Trial Profile
Study With SYL040012. Tolerance and Effect on Intraocular Pressure in Subjects With IOP '= 21 mm Hg.
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 23 Jul 2014
Price :
$35
*
At a glance
- Drugs Bamosiran (Primary)
- Indications Ocular hypertension; Open-angle glaucoma
- Focus Adverse reactions
- Sponsors Sylentis
- 07 May 2014 New trial record